The abstract is read at the publisher; the summary is JClub's.
Avatrombopag corrected persistent chemotherapy-induced thrombocytopenia in GI cancer patients, achieving the primary endpoint in 70% versus 17% with placebo.
- Why it matters: Persistent CIT limits full-dose, on-time chemotherapy delivery, and there is no widely available approved therapy for this common GI cancer complication.
- What they did: In a multicenter randomized double-blind US phase II trial, GI cancer patients with platelets ≤85×10^9/L on day 1 despite recovery time received avatrombopag or placebo 1:1.
- The result: The study stopped early for efficacy: 16/23 on avatrombopag met platelet recovery and recurrence prevention criteria versus 4/24 on placebo (P<.001), with higher adverse events (78% vs 46%) but no serious drug-related events.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.